GLP-1s changed everything. But they’re not the whole story.

The future of weight loss doesn’t rely on one molecule — it demands a smarter, multi-pathway protocol.

That’s why STAAR GPS™ was born.

The Limitations of GLP-1 Therapy Alone

GLP-1 receptor agonists like semaglutide and dulaglutide have revolutionized the weight loss industry, but patients and providers are now facing plateaus, side effects, and skyrocketing costs.

Here’s what we’ve learned from the front lines of real-world use:

Initial weight loss slows or stalls after 8–12 weeks
Lean muscle mass can decline, impacting long-term metabolism
Insulin resistance can persist, especially in stubborn cases
Access is shrinking due to FDA restrictions and branded drug prices ($1,000+/month)

GLP-1 alone is no longer enough.

The STAAR GPS Protocol™: A Smarter Way Forward

STAAR GPS™ stands for:

GLP-1 (e.g., liraglutide or dulaglutide)

Pramlintide

SLM+ by STAAR LABS

This protocol tackles weight loss through three synergistic metabolic pathways:

Appetite Suppression — via GLP-1 & amylin analogs
Gastric Emptying Delay — improves satiety and glucose control
Metabolic Optimization — through SLM+ supporting GIP-like activity, insulin sensitivity, and lean mass protection

Each component serves a distinct function. Together, they deliver sustained results.

What Happens When You Combine GLP-1 + Pramlintide + SLM+?

Research-Backed Synergy:

GLP-1 + Pramlintide: Co-administration boosts weight loss by enhancing satiety and suppressing appetite more than GLP-1 alone (clinical trials confirm amylin’s additive benefits).
SLM+: targeting insulin sensitivity, fat metabolism, and glucose control — while also providing GIP-like support without the GIP receptor may enhance weight loss by up to 50% more than GLP-1 alone..

Why Muscle Preservation Matters

GLP-1s often reduce total weight, but not always fat mass. Losing muscle weakens your metabolism and increases long-term weight regain risk.

SLM+ was engineered to address this exact problem, helping preserve lean tissue and energy expenditure during calorie reduction.

What Makes GPS™ the Future of Clinical Protocols?

This is next-generation protocol design — created by clinicians, supported by innovation, and informed by real-world results.

How to Get Started

STAAR GPS is currently available in two prescription-based options:

GPS-L™: Liraglutide + Pramlintide + SLM+
GPS-D™: Dulaglutide + Pramlintide + SLM+

📍 For Patients: Ask your clinic about STAAR GPS™

📍 For Clinics: Join our provider network

Provider Insight

“I used to rely on semaglutide alone, but my patients hit a wall. With GPS, we’ve seen better results, fewer plateaus, and a stronger metabolic foundation.”

— Dr. Caroline M., MD | Endocrinologist

Summary

GLP-1s opened the door.

STAAR GPS™ maps the path forward.

It’s time for a multi-targeted, muscle-sparing, research-informed approach to weight loss — and it starts with GPS.

Disclaimers

Medical Disclaimer: This content is provided for informational and educational purposes only and is not intended as medical advice. The STAAR GPS Protocol™ involves prescription medications that must be prescribed and managed by a licensed healthcare provider. Individual results may vary, and treatment decisions should be made based on clinical judgment and patient-specific factors.

Supplement Disclaimer: SLM+ by STAAR LABS is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. SLM+ should not be considered a replacement for medical treatment or medication unless directed by a healthcare provider.

Compliance Note: STAAR LABS does not sell prescription medications. All pharmaceuticals referenced in the GPS Protocol™ are available only through licensed providers and compounding pharmacies operating in compliance with state and federal law.

Research & Innovation Disclosure: STAAR LABS collaborates with clinics, pharmacies, and healthcare professionals to advance innovation in real-world metabolic health protocols. Our research focuses on the integration of nutraceutical and pharmaceutical strategies to support improved outcomes. This content may reference investigational or emerging clinical practices that require further validation.